Efficacy and Safety Evaluation of Human Reovirus Type 3 in Immunocompetent Animals
Open Access
- 15 December 2004
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 10 (24) , 8561-8576
- https://doi.org/10.1158/1078-0432.ccr-04-0940
Abstract
Purpose: Human reovirus type 3 has been proposed to kill cancer cells with an activated Ras signaling pathway. The purpose of this study was to investigate the efficacy of reovirus in immunocompetent glioma animal models and safety/toxicity in immunocompetent animals, including nonhuman primates. Experimental Design: Racine glioma cells 9L and RG2 were implanted s.c. or intracranially in Fisher 344 rats with or without reovirus antibodies, followed by treatment of reovirus. To study whether reovirus kills contralateral tumors in the brain and to determine viral distribution, we established an in situ dual tumor model followed by reovirus intratumoral inoculation only into the ipsilateral tumor. To evaluate neurotoxicity/safety of reovirus, Cynomolgus monkeys and immunocompetent rats were given intracranially with reovirus, and pathological examination and/or behavioral studies were done. Viral shedding and clinical biochemistry were systematically studied in monkeys. Results: Intratumorally given reovirus significantly suppressed the growth of both s.c. and intracranially tumors and significantly prolonged survival. The presence of reovirus-neutralizing antibodies did not abort the reovirus’ antitumor effect. Reovirus inhibited glioma growth intracranially in the ipsilateral but not the contralateral tumors; viral load in ipsilateral tumors was 15 to 330-fold higher than the contralateral tumors. No encephalitis or behavioral abnormalities were found in monkeys and rats given reovirus intracranially. No treatment-related clinical biochemistry changes or diffuse histopathological abnormality were found in monkeys inoculated intracranially with Good Manufacturing Practice prepared reovirus. Microscopic changes were confined to the region of viral inoculation and were dose related, suggesting reovirus intracranially was well tolerated in nonhuman primates. Conclusions: These data show the efficacy and safety of reovirus when it is used in the treatment of gliomas in immunocompetent hosts. Inoculation of reovirus into the brain of nonhuman primates did not produce significant toxicities.Keywords
This publication has 41 references indexed in Scilit:
- Reovirus as an experimental therapeutic for brain and leptomeningeal metastases from breast cancerGene Therapy, 2004
- Reovirus oncolysis as a novel purging strategy for autologous stem cell transplantationBlood, 2003
- Viral Shedding and Biodistribution of G207, a MuItimutated, Conditionally Replicating Herpes Simplex Virus Type 1, after Intracerebral Inoculation in AotusMolecular Therapy, 2000
- Vesicular Stomatitis Virus (VSV) Therapy of TumorsIUBMB Life, 2000
- Vesicular Stomatitis Virus (VSV) Therapy of TumorsIUBMB Life, 2000
- An oncolytic viral mutant that delivers the CYP2B1 transgene and augments cyclophosphamide chemotherapyNature Biotechnology, 1998
- Treatment of intracranial gliomas in immunocompetent mice using herpes simplex viruses that express murine interleukinsGene Therapy, 1998
- Long-Term Survival in a Rodent Model of Disseminated Brain Tumors by Combined Intrathecal Delivery of Herpes Vectors and Ganciclovir TreatmentHuman Gene Therapy, 1996
- Place navigation by rats in a swimming pool.Canadian Journal of Psychology / Revue canadienne de psychologie, 1984
- Place navigation impaired in rats with hippocampal lesionsNature, 1982